Loc Le

Loc Le

Auto-generated profile, based on publicly available information

Loc Le

Bladder Immunology Group, Biomedical Research Institute, Rockville, Maryland, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Infection and Immunity
Verified
Journal Article
Open access
EMEvaristus C Mbanefo
Evaristus C Mbanefo
CFChi-Ling Fu
Chi-Ling Fu
CHChristina P. Ho
Christina P. Ho
LLLoc Le
Loc Le
KIKenji Ishida
Kenji Ishida
MHMichael H. Hsieh
Michael H. Hsieh
Interleukin-4 (IL-4) is crucial in many helminth infections, but its role in urogenital schistosomiasis, infection withSchistosoma haematobiumworms, remains poorly understood due to a historical lack of animal models. The bladder pathology of urogenital schistosomiasis is caused by immune responses to eggs deposited in the bladder wall. A range of pathology occurs, including urothelial hyperplasia and cancer, but associated mechanisms and links to IL-4 are largely unknown.

1 June 2018 in Pathology
Verified
Journal Article
Closed access
LLLoc Le
Loc Le
AMAdebayo J. Molehin
Adebayo J. Molehin
SNStewart Nash
Stewart Nash
SSSouad R. Sennoune
Souad R. Sennoune
GAGul Ahmad
Gul Ahmad
ASAfzal Siddiqui
Afzal Siddiqui

3 April 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
EMEvaristus C Mbanefo
Evaristus C Mbanefo
LLLoc Le
Loc Le
LPLuke F. Pennington
Luke F. Pennington
JOJustin I. Odegaard
Justin I. Odegaard
TJTheodore S. Jardetzky
Theodore S. Jardetzky
MHMichael H. Hsieh
Michael H. Hsieh
Chemotherapy‐induced hemorrhagic cystitis (CHC) can be difficult to manage. Prior work suggests that IL‐4 alleviates ifosfamide‐induced hemorrhagic cystitis (IHC), but systemically administered IL‐4 causes significant side effects. We hypothesized that the Schistosoma hematobium homolog of IL‐4‐inducing principle from Schistosoma mansoni eggs (H‐IPSE), would reduce IHC and associated bladder pathology. IPSE binds IgE on basophils and mast cells, triggering IL‐4 secretion by these cells. IPSE is also an “infiltrin,” translocating into the host nucleus to modulate gene transcription. Mice were administered IL‐4, H‐IPSE protein or its nuclear localization sequence (NLS) mutant, with or without neutralizing anti‐IL‐4 antibody, or 2‐mercaptoethane sulfonate sodium (MESNA; a drug used to prevent IHC), followed by ifosfamide. Bladder tissue damage and hemoglobin content were measured. Spontaneous and evoked pain, urinary frequency, and bladdergene expression analysis were assessed. Pain behaviors were interpreted in a blinded fashion. One dose of H‐IPSE was superior to MESNA and IL‐4 in suppressing bladder hemorrhage in an IL‐4‐dependent fashion and comparable with MESNA in dampening ifosfamide‐triggered pain behaviors in an NLS‐dependent manner. H‐IPSE also accelerated urothelial repair following IHC. Our work represents the first therapeutic exploitation of a uropathogen‐derived host modulatory molecule in a clinically relevant bladder disease model and indicates that IPSE may be an alternative to MESNA for mitigating CHC.—Mbanefo, E. C., Le, L., Pennington, L. F., Odegaard, J. I., Jardetzky, T. S., Alouffi, A., Falcone, F. H., Hsieh, M. H. Therapeutic exploitation of IPSE, a urogenital parasite‐derived host modulatory protein, for chemotherapy‐induced hemorrhagic cystitis. FASEB J . 32, 4408–4419 (2018). www.fasebj.org

13 May 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MMMaria del Mar Maldonado
Maria del Mar Maldonado
MGMaria Gracia-Hernandez
Maria Gracia-Hernandez
LLLoc Huu Le
Loc Huu Le
MIMasafumi Iida
Masafumi Iida
JGJames L Gulley
James L Gulley
DHDuane H Hamilton
Duane H Hamilton
Background Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carcinomas and may represent novel immunotherapeutic targets. This study characterizes the ERV envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine. Methods The expression of ERVMER34-1 in multiple healthy adult and cancer tissues was assessed, as was its immunogenicity, to ascertain whether specific T cells could lyse human carcinoma cell lines expressing ERVMER34-1. Furthermore, the ability of a rationally designed ERVMER34-1-targeted therapeutic vaccine to induce tumor clearance in two murine carcinoma models expressing ERVMER34-1 was examined either as a monotherapy or in combination with anti-programmed cell death protein-1/programmed death-ligand 1 monoclonal antibody (mAb) or the interleukin-15 superagonist N-803. Results The ERVMER34-1 protein was shown to be overexpressed in 232/376 of human carcinomas analyzed while being absent in most healthy adult tissues. High levels of ERVMER34-1 RNA expression associate with decreased survival in uveal melanoma, adenoid cystic, and head and neck carcinomas. ERVMER34-1-specific T cells were detected in peripheral blood mononuclear cells (PBMCs) of patients with cancer but not healthy donors following an overnight stimulation. However, reactive T cells are readily expanded from both healthy donor and patient with cancer PBMCs following a 7- day in vitro stimulation. Furthermore, ERVMER34-1-specific T cells selectively kill human carcinoma cell lines expressing ERVMER34-1. A novel, rationally designed, therapeutic cancer vaccine targeting ERVMER34-1 mediated tumor control in established syngeneic murine tumors expressing the full-length ERVMER34-1 protein. When combined with checkpoint blockade, the vaccine promoted expansion of neoepitope-reactive T cells whose function was further enhanced when combined with N-803. This expansion of neoepitope-reactive T cells was associated with tumor control. Conclusions This study reveals the potential of a vaccine that targets the retroviral envelope protein ERVMER34-1 and supports its continued development toward clinical testing as a new class of therapeutic cancer vaccine.

29 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KIKenji Ishida
Kenji Ishida
DODerick N. M. Osakunor
Derick N. M. Osakunor
MRMario Rossi
Mario Rossi
OLOlivia K. Lamanna
Olivia K. Lamanna
EMEvaristus C Mbanefo
Evaristus C Mbanefo
MHMichael H. Hsieh
Michael H. Hsieh
Background: Parasitic flatworms of the Schistosoma genus cause schistosomiasis, which affects over 230 million people. Schistosoma haematobium causes the urogenital form of schistosomiasis (UGS), which can lead to hematuria, fibrosis, and increased risk of secondary infections by bacteria or viruses. UGS is also linked to bladder cancer. To understand the bladder pathology during S. haematobium infection, our group previously developed a mouse model that involves the injection of S. haematobium eggs into the bladder wall. Using this model, we studied changes in epigenetics profile, as well as changes in gene and protein expression in the host bladder tissues. In the current study, we expand upon this work by examining the expression level of both host and parasite genes using RNA sequencing (RNA-seq) in the mouse bladder wall injection model of S. haematobium infection. Methods: We used a mouse model of S. haematobium infection in which parasite eggs or vehicle control were injected into the bladder walls of female BALB/c mice. RNA-seq was performed on the RNA isolated from the bladders four days after bladder wall injection. Results/Conclusions: RNA-seq analysis of egg- and vehicle control-injected bladders revealed the differential expression of 1025 mouse genes in the egg-injected bladders, including genes associated with cellular infiltration, immune cell chemotaxis, cytokine signaling, and inflammation We also observed the upregulation of immune checkpoint-related genes, which suggests that while the infection causes an inflammatory response, it also dampens the response to avoid excessive inflammation-related damage to the host. Identifying these changes in host signaling and immune responses improves our understanding of the infection and how it may contribute to the development of bladder cancer. Analysis of the differential gene expression of the parasite eggs between bladder-injected versus uninjected eggs revealed 119 S. haematobium genes associated with transcription, intracellular signaling, and metabolism. The analysis of the parasite genes also revealed fewer transcript reads compared to that found in the analysis of mouse genes, highlighting the challenges of studying parasite egg biology in the mouse model of S. haematobium infection. Author summary: More than 230 million people worldwide are estimated to carry infection with parasites belonging to the Schistosoma genus, which cause morbidity associated with parasite egg deposition. Praziquantel, the drug of choice to treat the infection, does not prevent reinfection, and its decades-long history as the main treatment raises concerns for drug resistance. Of the schistosome species, Schistosoma haematobium causes urogenital disease and has a strong association with bladder cancer. The possibility for drug resistance and the gap in knowledge with respect to the mechanisms driving S. haematobium -related bladder cancer highlight the need to better understand the biology of the infection to aid in the development of new therapeutic strategies. In this study, we used a mouse model of S. haematobium infection that delivers parasite eggs directly to the host mouse bladder wall, and we examined the changes in the gene expression profile of the host and the parasite by RNA-sequencing. The results corroborated previous findings with respect to the host’s inflammatory responses against the parasite eggs, as well as revealed alterations in other immune response genes that deepen our understanding of the mechanisms involved in urogenital schistosomiasis pathogenesis.